Evidence map›Paper›PMID 41479703›Full record

ArticleWorld journal of gastrointestinal surgery2025

Very early recurrence after pancreatic cancer resection: Unmasking the "biological R2" enigma and rethinking prognostic paradigms.

Peng Wan, Shi-Qiong Zhou, Qing-Hua Ke

Abstract readLetter
In one paragraph

Article in World journal of gastrointestinal surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Peng WanDepartment of Chemoradiotherapy, Jingzhou No. 1 People's Hospital and First Affiliated Hospital of Yangtze University, Jingzhou 434000, Hubei Province, China.
Shi-Qiong ZhouDepartment of Chemoradiotherapy, Jingzhou No. 1 People's Hospital and First Affiliated Hospital of Yangtze University, Jingzhou 434000, Hubei Province, China.
Qing-Hua KeDepartment of Chemoradiotherapy, Jingzhou No. 1 People's Hospital and First Affiliated Hospital of Yangtze University, Jingzhou 434000, Hubei Province, China. 3803354759@qq.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC), a "silent killer" with elusive early symptoms and poor prognosis, sees nearly half of patients experience recurrence within a year post-curative-intent surgery. Very early recurrence (VER), defined as recurrence within 12 weeks postoperatively and first termed "biological R2 resection" by Belfiori

Indexed as

Biological R2 resectionPancreatic ductal adenocarcinomaPrognostic factorsRisk stratificationVery early recurrence

Identifiers

PMID41479703
PMCPMC12754472

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.